Nello Mainolfi - Aug 8, 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce N. Jacobs, Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Aug 8, 2023
Transactions value $
$24,960
Form type
4
Date filed
8/8/2023, 04:30 PM
Previous filing
Mar 3, 2023
Next filing
Nov 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $25K +12K +2.09% $2.08* 587K Aug 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -12K -83.52% $0.00 2.37K Aug 8, 2023 Common Stock 12K $2.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This number includes 870 shares acquired under the Registrant's employee stock purchase plan on May 31, 2023.
F2 The shares underlying this stock option vested in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.